Crohn's and Colitis Congress 2023

A combination regimen comprising two herbal extracts – curcumin and Qing Dai (QD) – have shown potential in the treatment of active* ulcerative colitis (UC), according to two trials from Israel presented at Crohn’s & Colitis Congress (CCC) 2023.

Data presented at the Crohn’s & Colitis Congress (CCC) 2023 reflect the benefit of vedolizumab for inflammatory bowel disease (IBD; Crohn’s disease and ulcerative colitis), be it alone or in a combination regimen. In one study however, extraintestinal manifestations were observed following vedolizumab use.

Children with Crohn’s disease (CD) are often treated with 5-aminosalicylate (5-ASA) contrary to guidelines, and this practice is associated with a substantial delay in initiating biologic therapy, according to a study presented at this year’s Crohn's & Colitis Congress.